10919nam 2200589 450 991048870230332120230412134137.09783030691868(electronic book)3-030-69186-1(CKB)5590000000519699(MiAaPQ)EBC6675926(Au-PeEL)EBL6675926(OCoLC)1259627319(PPN)269145850(EXLCZ)99559000000051969920220327d2021 uy 0engurcnu||||||||txtrdacontentcrdamediacrrdacarrierCannabinoids and pain /Samer N. Narouze, editorCham, Switzerland :Springer,[2021]©20211 online resource (xix, 339 pages) illustrations (black and white)3-030-69185-3 Includes bibliographical references and index.Part I: Introduction to Cannabis -- 1: History of Cannabis -- 2: Cannabis Regulations -- Introduction -- Federal Regulations -- State Cannabis Laws -- Research Expansion -- Conclusion -- 3: The Demand for Medical Cannabis Education -- 4: Pain Physicians and Medical Cannabis: Attitudes, Believes, Preparedness and Knowledge -- Introduction -- Development and Description of the Applied Questionnaire -- Statistical Analysis -- Results -- Discussion -- Summary -- Medical Cannabis Questionnaire -- 5: Cannabis Terminology -- Introduction -- General Aspects of the Cannabis Plant -- Differences Between C. sativa and C. indica -- Cannabis Versus Hemp -- The Endocannabinoid System (ECS) -- Key Terminology -- Cannabis Products and Accessories -- Conclusion -- Part II: Cannabinoids Pharmacology -- 6: The Endocannabinoid System -- Introduction -- Brief History of Cannabis and Hemp -- Components of the Endocannabinoid System (ECS) -- eCBs and Their Signal Transduction Pathways -- Complexity of the Endogenous Cannabinoid System -- CB1 and CB2 Receptor -- Other Receptors -- Transporters -- Enzymes -- Physiological Actions of ECS -- 7: Cannabinoid Receptor 1 (CB1) -- CB1 Receptors -- CB1 Receptor Physiology, Pathology, and Pharmacology -- CB1 Signaling -- CB1 Receptor Distribution -- Neocortex -- Hippocampus -- Hypothalamic -- Midbrain Periaqueductal Gray -- Brain Stem Rostral Ventromedial Medulla -- Tolerance -- CB1 Receptor Ligands -- References -- 8: Cannabinoid Receptor 2 (CB2) -- Cannabinoid 2 Receptor -- CB2 Receptor Physiology and Pharmacology -- CB2 Receptor Distribution -- CB2 Signaling -- CB2 Chronic Pain Models -- Tolerance -- CB2 Receptor Ligands.9: Endocannabinoids: Anandamide and 2-Arachidonoylglycerol (2-AG) -- Introduction -- Biosynthesis and Breakdown Pathways -- Anandamide -- 2-AG -- Endocannabinoids' Mechanism of Action -- Anandamide -- 2-AG -- Plasticity of Endocannabinoid Signaling -- Endocannabinoids in Pain -- Peripheral Mechanisms -- Spinal Mechanisms -- Supraspinal Mechanisms -- Conclusion -- 10: Phytocannabinoids: Tetrahydrocannabinol (THC) -- Phytocannabinoids -- Introduction -- Δ9-Tetrahydrocannabinol (THC) -- Mechanism of Action of THC -- Applied Pharmacology and Pharmacokinetics -- Absorption -- Smoking -- Oral -- Oro-mucosal and Intranasal -- Rectal -- Transcutaneous -- Distribution -- Metabolism and Elimination -- Conclusion -- 11: Phytocannabinoids: Cannabidiol (CBD) -- Phytocannabinoids -- Cannabidiol and Its Various Clinical Effects -- Pharmacodynamics of Cannabidiol -- Applied Pharmacology and Pharmacokinetics -- Smoking -- Oral -- Transcutaneous -- Volume of Distribution -- Metabolism -- Elimination -- Safety Profile and Side Effects -- Cannabidiol Interaction with Tetrahydrocannabinol -- Conclusion -- 12: Other Phytocannabinoids -- Introduction -- Synthesis of Phytocannabinoids -- Cannabinoids and the Endocannabinoid System (ECS) -- Minor Cannabinoids -- Cannabinol (CBN) -- Cannabigerol (CBG) -- Cannabichromene (CBC) -- Tetrahydrocannabivarin (THCV) -- Conclusion -- 13: Cannabis Drug Interactions -- Introduction -- Routes of Administration -- Cannabinoid Drug Interactions -- Specific Drug Interactions -- Over-the-Counter (OTC) Analgesics -- Neuropathic Agents -- Opiates -- Antiepileptics -- Psychotropics -- Anticoagulants and Antiplatelets: "Blood Thinners" -- Warfarin -- Direct Oral Anticoagulants -- Clopidogrel -- Heparin/Fondaparinux -- References -- Part III: Pharmaceutical Cannabinoids.14: Dronabinol (Marinol®) -- Introduction -- Mechanism of Action -- Pharmacokinetics -- Therapeutic Use -- Safety, Toxicity, and Adverse Effects -- 15: Nabilone (Cesamet) -- Introduction -- Clinical Trials -- Pharmacology and Pharmacokinetics -- Dosage and Administration -- Monitoring, Adverse Events, Drug Interactions, and Abuse Potential -- Adverse Effects -- Drug Interactions -- Abuse Potential -- 16: Cannabidiol (Epidiolex) -- Introduction -- Clinical Trials -- Pharmacology and Pharmacokinetics -- Dosage and Administration -- Monitoring, Adverse Events, and Drug Interactions -- Adverse Effects -- Abuse Potential -- 17: Nabiximols (Sativex®) -- Introduction -- Nabiximols Production -- Nabiximols Approval and Indications -- Nabiximols Contraindication -- Nabiximols Evidence -- Nabiximols for MS-Related Spasticity -- Nabiximols for MS-Related Neuropathic Pain -- Nabiximols for Cancer-Related Pain -- Nabiximols for Chronic Pain -- Nabiximols Tolerability -- Nabiximols Dosage and Administration -- Administration -- Dosing -- Storage, Stability, and Dosage Form -- Storage and Stability -- Dosage Form -- Summary -- Part IV: Medical Cannabis -- 18: Cannabis Strains to Chemovars -- Introduction -- Cannabis sativa L. -- Cannabis Cultivation and Trichomes -- Importance of Trichomes -- Cannabis Constituents -- Cannabinoids -- Terpenoids -- Other Cannabis Compounds -- Entourage Effect of Cannabis Constituents -- Cannabis Classification: Strains Versus Chemovars -- Strains -- Chemovar -- Practical Chemovar Selection for Clinicians -- Summary -- 19: The Model of a Medical Cannabis Clinic -- Introduction -- Description of a Medical Cannabis Clinic -- Referral and Screening -- Initial Visit -- Follow-Up and Monitoring -- Patient Education and Physician Communication.Protocols and Procedure Guidelines -- Continuing Medical Education -- Research Development -- Conclusion -- References -- 20: Barriers for the Prescription of Cannabinoid-Based Medicines -- Introduction -- Barriers for Cannabinoid Prescription -- Social Stigma for the Use of Cannabis -- Myths Versus Realities of Medical Cannabis Use -- Research Gaps and Limitations to Justify Medical Cannabis Use -- Lack of Knowledge Regarding Cannabis Regulatory Frameworks -- Limited Medical Cannabis Education -- Development of Medical Cannabis Education Programs with High Scientific Content -- Conclusion -- 21: Practical Recommendations for the Use of Medical Cannabis -- Introduction -- Cannabinoid-Based Medicines: What Is Currently Available? -- Prescription or Pharmaceutical Cannabinoids -- Natural Cannabis -- Inhalation -- Practical Recommendations [11, 12] -- Oral Administration -- Practical Recommendations [11, 12] -- Therapeutic Properties of Cannabinoids: THC Versus CBD -- Practical Recommendations for the Prescription of Cannabinoid-Based Medicines -- Clinical Evidence to Support Cannabinoid Use in Specific Medical Conditions -- Is the Patient a Candidate for Cannabinoid Therapy? A Systematic Approach -- Conclusion -- 22: Cannabinoid-Based Medicines: Dosing, Titration &amp -- Monitoring -- Introduction -- Methods of Administration -- Inhalation: Smoking and Vaporizing -- Oral -- Oromucosal -- Topical -- Dosing -- Concentration and Potency -- Cannabis Flower Dosing -- Cannabis Oil Dosing -- Achieving Optimal Therapeutic Dose and Cannabis Rotation -- Cannabis Chemovar Rotation and Reduction -- Monitoring -- Summary -- 23: Cannabinoid-Based Medicines: Patient Safety Considerations -- Introduction -- Practical Considerations for Cannabis Use -- Considerations -- Immunocompromised Patients.Calcineurin Inhibitors, Protein Disulfide Isomerase (PD1) Inhibitors, and Biologics -- Chronic Kidney Disease -- Older Adults and Patients with Concurrent Medical Conditions -- Polypharmacy and Drug Interactions [10] -- Precautions -- Concurrent Active Mood or Anxiety Disorder -- Patients with Risk Factors for Cardiovascular Disease (CVD) -- Tobacco Use -- E-Cigarette Use -- Severe Liver Dysfunction or Disease -- Medications Associated with Sedation or Cognitive Impairment -- Driving and Safety Sensitive Occupations -- Relative Contraindications -- Individuals Under the Age of 25 -- Cannabis Use Disorder (CUD) -- Substance Use Disorder (SUD) and Consideration for Harm Reduction -- Contraindications -- Cardiovascular Disease -- Respiratory Disease -- Psychosis and Bipolar Disorders -- Pregnancy and Breastfeeding -- Summary -- Part V: Cannabinoids and Pain -- 24: Cannabinoids and Pain: Mechanisms of Action -- Introduction -- Endocannabinoids' Mechanism of Action -- Anandamide (AEA) -- 2-Arachidonoylglycerol (2-AG) -- Endocannabinoids and Pain Modulation -- Peripheral Mechanisms -- Spinal Mechanisms -- Supraspinal Mechanisms -- Anandamide and 2-AG Synergistic Effect -- Endocannabinoid Receptors -- CB1 Receptors -- Central CB1 Receptors -- Peripheral CB1 Receptors -- Central CB2 Receptors -- Peripheral CB2 Receptors -- Other Putative Endocannabinoid Receptors: TRPV1 and GPR55 -- TRPV1 -- GPR55 -- Phytocannabinoids (THC and CBD) -- THC -- CBD -- Mechanisms of Action in Pain Modulation -- THC -- CBD -- References -- 25: Cannabinoids and Pain: Clinical Evidence -- Introduction -- Chronic Non-cancer Pain -- Chronic Neuropathic Pain -- Fibromyalgia -- Rheumatoid Arthritis -- Cancer Pain -- Acute Nociceptive Pain -- Summary -- 26: Cannabinoids and Cancer Pain -- Introduction -- Relevant Mechanisms of Cancer Pain.Current Understanding of Clinical Studies.This book presents a well-balanced view of the potential medical use of cannabinoids in pain. It comprehensively covers the current challenges with medical cannabis utilization and provides recommendations for research and future directions.CannabinoidsTherapeutic usePainChemotherapyCànnabisthubÚs terapèuticthubLlibres electrònicsthubCannabinoidsTherapeutic use.PainChemotherapy.CànnabisÚs terapèutic615.7827Narouze Samer N.MiAaPQMiAaPQMiAaPQBOOK9910488702303321Cannabinoids and Pain2785335UNINA01024nam2 22002891i 450 USM189875920231121125916.0978887642203420130919d2011 ||||0itac50 baitaitz01i xxxe z01n1: (Satt. 1-6)PisaEdizioni della Normale2011LXXXIII, 454 p.25 cm.Testi e commenti11001RAV13529612001 Testi e commenti11001PIS00366282001 Scholia in Iuvenalem recentiorasecundum recensiones Φ et Χedizione critica a cura di Stefano Grazzini1ITIT-0120130919IT-FR0017 Biblioteca umanistica Giorgio ApreaFR0017 USM1898759Biblioteca umanistica Giorgio Aprea 52S.SIJ. LL1 Iuv.Gra.1 52SBA0000130285 VMN RS C 2013091920130919 521: (Satt. 1-6)3642868UNICAS02522nam 2200565 a 450 991079584770332120240102112707.001997810799780199781072(MiAaPQ)EBC7034525(CKB)24235121400041(MiAaPQ)EBC716677(Au-PeEL)EBL716677(CaPaEBR)ebr10472272(CaONFJC)MIL312127(OCoLC)729872814(EXLCZ)992423512140004120100827d2011 uy 0engur|||||||||||God's arbiters[electronic resource] Americans and the Philippines, 1898-1902 /by Susan K. HarrisOxford ;New York Oxford University Press2011xii, 257 p., [15] p. of plates illImagining the AmericasIncludes bibliographical references and index.Introduction: A Christian nation -- section 1: American narratives -- Citizenship and the Philippine debates : the religious factor -- Citizenship and the Philippine debates : the racial factor -- section 2: Creating citizens -- A Connecticut Yankee in the Philippines -- The national Christian -- section 3: The eyes of the world -- "The White man's burden," the Philippines, and the Anglo-American alliance -- "Saxon eyes and barbaric souls" : non-Anglo responses to the American annexation of the Philippines -- Noli me tangere : Filipino responses to annexation.Imagining the Americas.RacismPolitical aspectsUnited StatesHistoryPolitical messianismUnited StatesHistoryChristianity and politicsUnited StatesHistoryImperialismHistoryUnited StatesForeign relationsPhilippinesPhilippinesForeign relationsUnited StatesPhilippinesAnnexation to the United StatesPhilippinesForeign public opinion, AmericanUnited StatesColonial questionUnited StatesTerritorial expansionRacismPolitical aspectsHistory.Political messianismHistory.Christianity and politicsHistory.ImperialismHistory.327.730599Harris Susan K.1945-1522567MiAaPQMiAaPQMiAaPQBOOK9910795847703321God's arbiters3762311UNINA